– pour le traitement des patients adultes présentant un cancer du poumon non à petites cellules (CPNPC) avancé porteur d’une mutation BRAFV600E L’avis positif du CHMP se base sur les résultats de l’étude de phase II PHAROS[1], qui a démontré un taux de réponse objective (ORR) de 75 % chez…

– If approved by the European Commission, zolbetuximab would become the first and only CLDN18.2-targeted therapy approved in the European Union – A decision on the EU marketing authorization is expected by October 2024 TOKYO, July 26, 2024 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503,…

– If approved, enfortumab vedotin in combination with pembrolizumab will be the first and only treatment to offer an alternative to platinum-containing chemotherapy, the current standard of care for those with unresectable or metastatic urothelial cancer – Positive opinion is based on…

PÉKIN, 26 juillet 2024 /PRNewswire/ — Pouvant s’enorgueillir de la richesse de ses zones humides, la ville de Harbin, dans la province du Heilongjiang au nord-est de la Chine, est devenue une destination touristique populaire pendant les jours d’été cette année. Depuis le début du mois…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.